ECSP088569A - Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares - Google Patents

Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares

Info

Publication number
ECSP088569A
ECSP088569A EC2008008569A ECSP088569A ECSP088569A EC SP088569 A ECSP088569 A EC SP088569A EC 2008008569 A EC2008008569 A EC 2008008569A EC SP088569 A ECSP088569 A EC SP088569A EC SP088569 A ECSP088569 A EC SP088569A
Authority
EC
Ecuador
Prior art keywords
treatment
cardiovascular diseases
furopirimidine
derivatives substituted
new acyclic
Prior art date
Application number
EC2008008569A
Other languages
English (en)
Inventor
Johannes Peter Stasch
Alexander Hillisch
Karl Heinz Schlemmer
Mario Jeske
Thomas Lampe
Rudolf Schohe-Loop
Gunter Karig
Andreas Knorr
Lars Baerfacker
Joachim Schuhmacher
Martina Klein
Eva-Maria Becker
Raimund Kast
Hartmut Beck
Friederike Stoll
Mark Meininghaus
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of ECSP088569A publication Critical patent/ECSP088569A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente solicitud se refiere a nuevos derivados de furopirimidina acíclicos sustituidos, a procedimientos para su producción, a su uso para el tratamiento y/o la profilaxis de enfermedades, así como a su uso para la preparación de producto medicinal para el tratamiento y/o la profilaxis de enfermedades, en particular para el tratamiento y/o profilaxis de enfermedades cardiovasculares.
EC2008008569A 2005-12-21 2008-06-20 Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares ECSP088569A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005061170A DE102005061170A1 (de) 2005-12-21 2005-12-21 Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung

Publications (1)

Publication Number Publication Date
ECSP088569A true ECSP088569A (es) 2008-08-29

Family

ID=37876878

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008569A ECSP088569A (es) 2005-12-21 2008-06-20 Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares

Country Status (31)

Country Link
US (1) US8183246B2 (es)
EP (1) EP1966217B1 (es)
JP (1) JP5254032B2 (es)
KR (1) KR101429777B1 (es)
CN (1) CN101384603B (es)
AR (1) AR058108A1 (es)
AU (1) AU2006334856B2 (es)
BR (1) BRPI0620317A2 (es)
CA (1) CA2633701C (es)
CR (1) CR10092A (es)
DE (1) DE102005061170A1 (es)
DK (1) DK1966217T3 (es)
DO (1) DOP2006000280A (es)
EC (1) ECSP088569A (es)
ES (1) ES2418855T3 (es)
GT (1) GT200800117A (es)
IL (1) IL192062A0 (es)
MA (1) MA30039B1 (es)
NO (1) NO20082986L (es)
NZ (1) NZ569214A (es)
PE (1) PE20071168A1 (es)
PL (1) PL1966217T3 (es)
PT (1) PT1966217E (es)
RU (1) RU2454419C2 (es)
SV (1) SV2009002953A (es)
TN (1) TNSN08279A1 (es)
TW (1) TWI405764B (es)
UA (1) UA94080C2 (es)
UY (1) UY30046A1 (es)
WO (1) WO2007079862A1 (es)
ZA (1) ZA200805385B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007019691A1 (de) * 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007027799A1 (de) * 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
DE102007054786A1 (de) * 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
EP2848621A4 (en) 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC RING CONNECTION
EP2848622A4 (en) 2012-05-10 2015-11-04 Takeda Pharmaceutical Aromatic ring compound
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
JP7254078B2 (ja) 2017-11-27 2023-04-07 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物
WO2020231990A1 (en) * 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
KR102094337B1 (ko) 2019-10-01 2020-03-27 안문호 금속이물질 제거장치
TW202233625A (zh) 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577420A (en) 1968-01-05 1971-05-04 Pfizer Certain 4-aminofuro(2,3-d)pyrimidines
ATE266662T1 (de) 1998-07-22 2004-05-15 Daiichi Suntory Pharma Co Ltd Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
EP1132093A4 (en) 1999-09-17 2006-04-19 Daiichi Suntory Pharma Co Ltd MEANS FOR PREVENTING OR PREVENTING MYOCARDITIS, CARDIOMYOPATHY DILATUS AND HEART FAILURE CONTAINING NF-KAPPA B INHIBITORS AS AN ACTIVE INGREDIENT
PT1390371E (pt) 2001-05-14 2006-07-31 Novartis Ag Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
DE10141212A1 (de) * 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
EP1425284A2 (en) 2001-09-11 2004-06-09 Smithkline Beecham Corporation Furo- and thienopyrimidine derivatives as angiogenesis inhibitors
DE10148883A1 (de) 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
WO2005121149A1 (en) 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
US7776867B2 (en) * 2004-06-29 2010-08-17 Amgen Inc. Furanopyrimidines

Also Published As

Publication number Publication date
CN101384603A (zh) 2009-03-11
JP2009520713A (ja) 2009-05-28
RU2008129363A (ru) 2010-01-27
AR058108A1 (es) 2008-01-23
US8183246B2 (en) 2012-05-22
RU2454419C2 (ru) 2012-06-27
DOP2006000280A (es) 2007-07-31
WO2007079862A1 (de) 2007-07-19
AU2006334856A1 (en) 2007-07-19
NZ569214A (en) 2011-07-29
PL1966217T3 (pl) 2013-09-30
TNSN08279A1 (en) 2009-10-30
DE102005061170A1 (de) 2007-07-05
TWI405764B (zh) 2013-08-21
CA2633701C (en) 2014-05-27
CN101384603B (zh) 2012-08-01
SV2009002953A (es) 2009-04-28
EP1966217A1 (de) 2008-09-10
CA2633701A1 (en) 2007-07-19
US20090318475A1 (en) 2009-12-24
GT200800117A (es) 2009-12-16
AU2006334856B2 (en) 2013-04-04
UY30046A1 (es) 2007-07-31
CR10092A (es) 2008-10-08
UA94080C2 (ru) 2011-04-11
PT1966217E (pt) 2013-07-12
ZA200805385B (en) 2009-10-28
TW200745132A (en) 2007-12-16
KR20080081323A (ko) 2008-09-09
EP1966217B1 (de) 2013-05-08
MA30039B1 (fr) 2008-12-01
IL192062A0 (en) 2008-12-29
ES2418855T3 (es) 2013-08-16
BRPI0620317A2 (pt) 2011-11-08
HK1130054A1 (en) 2009-12-18
NO20082986L (no) 2008-07-02
DK1966217T3 (da) 2013-08-05
PE20071168A1 (es) 2008-02-07
JP5254032B2 (ja) 2013-08-07
KR101429777B1 (ko) 2014-08-19

Similar Documents

Publication Publication Date Title
ECSP088569A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares
UY27878A1 (es) Derivados de indolinfenilsulfonamida
ECSP12012125A (es) Ariltriazolonas ligadas a bisarilo y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
HN2011002406A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
ECSP077340A (es) Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa
CU24011B1 (es) Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
CR11869A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CU20080122A7 (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
HN2008000946A (es) Nuevos derivados de furopirimidina aciclicos sustituidos
DOP2003000663A (es) Derivados de indolinfenilsulfonamida
UY29247A1 (es) Amidas de ácido pirazindicarboxílico y su uso
DOP2005000177A (es) Nuevos derivados de pirimidina y su uso
DOP2005000174A (es) Fenilaminotiazoles sustituidos y su uso
DOP2009000093A (es) Dihidropirazolonas sustituídas para el tratamiento de enfermedades cardiovasculares y hematológicas